文献速递儿童心血管与肾脏儿童血液肿瘤与免疫

利伐沙班治疗儿童冠状动脉疾病的有效性与安全性病例系列研究

[Effectiveness and safety of rivaroxaban in pediatric patients with coronary artery diseases: a case series study].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-03-14

该病例系列研究纳入84例接受抗血小板联合利伐沙班治疗的儿童冠状动脉疾病患儿,主要适应证为川崎病合并冠状动脉病变(98%)。随访期间无新发血栓,1例发生严重心血管不良事件,无严重出血,4例发生临床相关非严重出血。15.0 mg/d等效剂量方案在≥24月龄患儿中有效性和安全性良好,<24月龄患儿建议监测抗Ⅹa因子活性指导个体化剂量。

要点

  • 84例患儿中无新发血栓,1例(1%)发生严重心血管不良事件,无严重出血。
  • 4例(5%)发生临床相关非严重出血事件。
  • ≥24月龄患儿中26%需剂量调整,<24月龄患儿中10例需调整剂量。

核心结论

  • 15.0 mg/d等效的利伐沙班剂量优化方案在≥24月龄冠状动脉疾病患儿中具有良好的有效性和安全性。
  • 对于<24月龄患儿,建议结合利伐沙班校正的抗Ⅹa因子活性监测进行个体化剂量调整。

研究设计与样本

  • 病例系列研究,纳入2024年1月至2025年10月在复旦大学附属儿科医院接受抗血小板联合利伐沙班治疗的84例冠状动脉疾病患儿。
  • 回顾性分析临床资料、血药浓度、抗凝监测结果及治疗结局,构建线性回归模型分析血药浓度与抗Ⅹa因子活性的相关性。

主要发现

  • 84例患儿中男66例(79%)、女18例(21%),开始使用利伐沙班时年龄86(51,129)月龄,体重24(15,40)kg,使用时间305(121,460)d。
  • 适应证包括川崎病合并冠状动脉病变82例(98%),冠状动脉瘘堵闭术后2例(2%)。
  • 研究期间发生1例(1%)严重心血管不良事件,未出现新发血栓,未见严重出血事件,4例(5%)发生临床相关非严重出血事件。
  • 69例≥24月龄组中18例(26%)需调整剂量,发生30次计划外调整;15例<24月龄组中10例需调整剂量,发生16次计划外调整。
  • 给药后2~4 h血药浓度为152(107,207)μg/L,利伐沙班校正的抗Ⅹa因子活性为126(80,186)μg/L,两者呈良好线性相关(血药浓度=抗Ⅹa因子活性×1.049+13.52,R²=0.919,P<0.001)。

关键数值与推荐

  • 利伐沙班初始剂量参考15.0 mg/d等效的剂量优化方案。
  • 给药后2~4 h血药浓度为152(107,207)μg/L,利伐沙班校正的抗Ⅹa因子活性为126(80,186)μg/L。
  • 血药浓度与利伐沙班校正的抗Ⅹa因子活性线性回归方程:血药浓度=抗Ⅹa因子活性×1.049+13.52,R²=0.919,P<0.001。

临床怎么用

  • ≥24月龄冠状动脉疾病患儿可采用15.0 mg/d等效的利伐沙班剂量优化方案,无需常规监测抗Ⅹa因子活性。
  • <24月龄患儿建议定期监测利伐沙班校正的抗Ⅹa因子活性以指导个体化剂量调整。
  • 抗血小板联合利伐沙班治疗期间需关注出血事件,尤其是临床相关非严重出血。

局限性

  • 本研究为单中心回顾性病例系列研究,样本量有限(84例),结论需更大规模前瞻性研究验证。
  • 随访时间有限,长期有效性和安全性尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the Effectiveness and safety of rivaroxaban in combination with antiplatelet therapy for treating pediatric coronary artery diseases. Methods: This case series study included 84 pediatric patients with coronary artery diseases who received antiplatelet therapy plus rivaroxaban at the Children's Hospital of Fudan University from January 2024 to October 2025. Clinical characteristics, rivaroxaban doses, rivaroxaban plasma concentration, anti-factor Ⅹa activity, and therapeutic outcomes were collected and analyzed. Linear regression was used to assess the relationship between plasma concentration and anti-factor Ⅹa activity. Results: Among the 84 patients, 66 were male (79%) and 18 were female (21%). The age and body weight at rivaroxaban initiation was 86 (51, 129) months and 24 (15, 40) kg, respectively. The treatment duration with rivaroxaban was 305 (121, 460) d. The initial dose followed a 15.0 mg/d targeted regimen. Indications included Kawasaki disease with coronary artery lesions (82 patients, 98%) and status post coronary artery fistula occlusion (2 patients, 2%). During follow-up, no new thrombotic events were observed; however, 1 patient (1%) experienced a major adverse cardiovascular event. No major bleeding events occurred, while 4 patients (5%) developed clinically relevant non-major bleeding. Regarding dose adjustment, among the 69 children aged ≥24 months, 18 (26%) required adjustment with 30 unplanned adjustments. In contrast, among the 15 children aged <24 months, 10 children required adjustment with 16 unplanned adjustments. The rivaroxaban plasma concentration at 2-4 hours post-administration was 152 (107, 207) μg/L, corresponding to the rivaroxaban calibrated anti-factor Ⅹa activity of 126 (80, 186) μg/L. A strong linear correlation was observed between plasma concentration and anti-factor Ⅹa activity (plasma concentration=1.049×anti-factor Ⅹa activity+13.52, R²=0.919, P<0.001). Conclusions: The 15.0 mg/d targeted rivaroxaban regimen demonstrates favorable effectiveness and safety in Chinese children aged 24 months or older with coronary artery diseases. However, for children younger than 24 months, regular monitoring of rivaroxaban-calibrated anti-factor Ⅹa activity is recommended to guide individualized dosing. 目的: 总结利伐沙班治疗儿童冠状动脉疾病的临床经验,评估其在抗血小板联合抗凝治疗背景下的有效性和安全性。 方法: 病例系列研究。选择2024年1月至2025年10月在复旦大学附属儿科医院接受抗血小板联合利伐沙班治疗的84例冠状动脉疾病患儿为研究对象,回顾性分析其临床资料、血药浓度、抗凝监测结果及治疗结局。构建线性回归模型,分析血药浓度与抗Ⅹa因子活性之间的相关性。 结果: 共纳入84例患儿,男66例(79%)、女18例(21%),开始使用利伐沙班时的年龄为86(51,129)月龄,体重为24(15,40)kg,利伐沙班使用时间为305(121,460)d。利伐沙班初始剂量参考15.0 mg/d等效的剂量优化方案。适应证包括川崎病合并冠状动脉病变82例(98%),冠状动脉瘘堵闭术后2例(2%)。研究期间发生1例(1%)严重心血管不良事件,未出现新发血栓,未见严重出血事件,4例(5%)发生临床相关非严重出血事件。69例≥24月龄组患儿中,18例(26%)需调整剂量,发生30次计划外调整;15例<24月龄组患儿中,10例需调整剂量,发生16次计划外调整。给药后2~4 h血药浓度为152(107,207)μg/L,利伐沙班校正的抗Ⅹa因子活性为126(80,186)μg/L。血药浓度和利伐沙班校正的抗Ⅹa因子活性呈良好的线性相关(血药浓度=利伐沙班校正的抗Ⅹa因子活性×1.049+13.52,R2=0.919,P<0.001)。 结论: 15.0 mg/d等效的利伐沙班剂量优化方案在≥24月龄冠状动脉疾病患儿中具有良好的有效性和安全性。对于<24月龄患儿,建议结合利伐沙班校正的抗Ⅹa因子活性监测进行个体化剂量调整。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dai AA, Xia HT, Xue X, et al. [Effectiveness and safety of rivaroxaban in pediatric patients with coronary artery diseases: a case series study]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41834203. doi:10.3760/cma.j.cn112140-20251102-00976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。